COVID-19 vaccines
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19 vaccines On the Web |
|
American Roentgen Ray Society Images of COVID-19 vaccines |
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: José Eduardo Riceto Loyola Junior, M.D.[2]
Overview
On December 11, 2020, the F.D.A. authorized Pfizer's vaccine for emergency use for the prevention of COVID-19. Since then, many other vaccines have been developed, such as the ones from Moderna, AstraZeneca, Janssen, Sinovac, Sinopharm and Gamaleya. Efficacy, side effect and safety profiles vary dramatically between them, as they are produced using different mechanisms.
Vaccines
Pfizer/BioNtech Comirnaty
It was approved for emergency use in December 11, 2020. It has been shown to have an efficacy of 91% at preventing COVID-19 in the course of six months. Its protection against severe COVID-19 was shown to be of approximately 97%. New analysis showed that after six months its efficacy fell to 84%, which is not known if this is due to the vaccine and immune system themselves of if the emergence of variants are affecting the efficacy of the vaccine. As for side effects, the vaccine has been reported to cause mostly mild symptoms such as myalgia, headaches and soreness in the location where it was applied. Allergic reactions have also been reported in a few patients who have allergy to PEG substances. It has also been reported to be associated with myocarditis, especially in young men, but the cases reported so far were mild and recovered.
Moderna
The clinical trials produced by Moderna showed that its vaccine has an efficacy of 90% against symptomatic COVID-19 and 95% efficacy against severe disease after six months. As its